Clinical Manifestations and Myositis-Specific Autoantibodies Associated with Physical Dysfunction after Treatment in Polymyositis and Dermatomyositis: An Observational Study of Physical Dysfunction with Myositis in Japan

<div>The J-HAQ-DI (a), PGA (b), and EGA (c) scores in enrolled PM/DM patients. Thirty percent of enrolled patients showed physical dysfunction (J-HAQ-DI &gt; 0.5) (a). The PGA (b) and EGA (c) scores were less than 10 in 40% and 80% of patients, respectively. J-HAQ-DI: Japanese version of the Health Assessment Questionnaire Disability Index; PGA: Patient Global Assessment; EGA: Evaluator’s Global Assessment.</div>

BioMed Research International

fig1

Figure 1

Figure 1: Clinical Manifestations and Myositis-Specific Autoantibodies Associated with Physical Dysfunction after Treatment in Polymyositis and Dermatomyositis: An Observational Study of Physical Dysfunction with Myositis in Japan 

Figure 1 | Clinical Manifestations and Myositis-Specific Autoantibodies Associated with Physical Dysfunction after Treatment in Polymyositis and Dermatomyositis: An Observational Study of Physical Dysfunction with Myositis in Japan 